Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
130.1 USD | -0.23% | +0.73% | +19.01% |
05-07 | CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab) | CI |
05-02 | Merck: encouraging results in gastric cancer | CF |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.01% | 330B | |
+33.00% | 700B | |
-5.01% | 358B | |
+3.57% | 287B | |
+15.89% | 236B | |
+6.52% | 202B | |
-9.24% | 197B | |
+5.69% | 161B | |
-2.61% | 157B | |
+3.41% | 124B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc., Q2 2023 Earnings Call, Aug 01, 2023